SCHEMBL25547019

SCHEMBL25547019

Cc1ncc(-c2cccs2)nc1C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.61
NPC1 O15118 6/20 0.61
KDM4E B2RXH2 11/20 0.59
ALDH1A1 P00352 8/20 0.59
SMN1; SMN2 Q16637 5/20 0.59
GAA P10253 5/20 0.59
HPGD P15428 4/20 0.59
HSD17B10 Q99714 4/20 0.59
CASP1 P29466 2/20 0.59
CASP7 P55210 2/20 0.59
MAPK10 P53779 1/20 0.59
MEN1 O00255 6/20 0.52
KMT2A Q03164 6/20 0.52
MAPT P10636 4/20 0.52
L3MBTL1 Q9Y468 3/20 0.52
TDP1 Q9NUW8 2/20 0.52
USP2 O75604 1/20 0.50
TP53 P04637 1/20 0.50
PDGFRB P09619 1/20 0.49
KIT P10721 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25544884 0.79 KDM4E (0.57) RAB9ANPC1KDM4EALDH1A1SMN1; SMN2
SCHEMBL20232427 0.77 KDM4E (0.63) RAB9ANPC1KDM4EALDH1A1SMN1; SMN2
SCHEMBL708998 0.74 NPC1 (1.00) RAB9ANPC1KDM4EALDH1A1SMN1; SMN2
SCHEMBL31393433 0.74 NPC1 (1.00) RAB9ANPC1KDM4EALDH1A1SMN1; SMN2
SCHEMBL20286586 0.74 NPC1 (0.53) RAB9ANPC1KDM4EALDH1A1SMN1; SMN2
SCHEMBL3424662 0.74 KDM4E (0.68) RAB9ANPC1KDM4EALDH1A1SMN1; SMN2
SCHEMBL12454616 0.73 KDM4E (0.62) RAB9ANPC1KDM4EALDH1A1SMN1; SMN2
SCHEMBL27960148 0.73 RAB9A (0.44) RAB9ANPC1KDM4EALDH1A1SMN1; SMN2
SCHEMBL19066630 0.73 NPC1 (0.96) RAB9ANPC1KDM4EALDH1A1SMN1; SMN2
SCHEMBL4149220 0.72 KDM4E (0.56) RAB9ANPC1KDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 RAB9A 1568/4885NPC1 2317/4885KDM4E 710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.